D.E. Shaw & Co’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
Other funds holding LGND
D.E. Shaw & Co's LGND Position: Q3 2026 in Review
D.E. Shaw & Co increased its Ligand Pharmaceuticals (LGND) stake by 11% in Q3 2026, buying an estimated $1.77M and bringing the position to 62,505 shares worth $19.5M. The position accounts for 0.01% of the portfolio, ranked #1321.
D.E. Shaw & Co first reported a position in LGND in Q2 2013 and has held it in 38 quarters since. The position peaked at $22.9M in Q4 2018. 431 funds tracked by Wall St. Rank hold LGND as of Q3 2026.
- D.E. Shaw & Co held 62,505 shares of Ligand Pharmaceuticals worth $19.5M as of Q3 2026.
- D.E. Shaw & Co bought 5,990 Ligand Pharmaceuticals shares in Q3 2026, an estimated $1.77M.
- Ligand Pharmaceuticals made up 0.01% of D.E. Shaw & Co's portfolio in Q3 2026, its #1321 holding.
- D.E. Shaw & Co first reported a position in Ligand Pharmaceuticals in Q2 2013 and has held it in 38 quarters since.
- D.E. Shaw & Co's Ligand Pharmaceuticals position peaked at $22.9M in Q4 2018.
- 431 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2026.
Based on D.E. Shaw & Co's 13F filing for Q3 2026, filed 16 Nov 2026.